Literature DB >> 11765223

Lung cancer associated with several connective tissue diseases: with a review of literature.

Y Yang1, J Fujita, M Tokuda, S Bandoh, T Ishida.   

Abstract

The association between connective tissue disease (CTD) and malignancy has been an area of debate. Whether this relation is casual or causal, it would seem that the importance of their possible relationship is twofold. The purpose of this study is to describe the clinical features of lung cancer associated with several CTDs. Patients with CTD associated with lung cancer were retrospectively evaluated. A review of the clinical features of 153 reported cases from 1944 to the present was conducted. There were 82 females and 71 males, with a median age of 58. Histological types of lung cancer were as follows, bronchioloalveolar cell carcinoma (39 cases), adenocarcinoma (36), squamous cell carcinoma (28), small cell lung cancer (27), large cell carcinoma (6), others (8), and unknown (10). There was a relationship between smoking and development of lung cancer in patients with rheumatoid arthritis (RA) and polymyositis/dermatomyositis (PM/DM). The majority of patients with progressive systemic sclerosis (PSS) who developed lung cancer were female, with underlying interstitial fibrosis, and most tumors were of bronchioloalveolar cell or adenocarcinoma cell type. Patient characteristics were significantly different among the various groups of CTD associated with lung cancer.

Entities:  

Mesh:

Year:  2001        PMID: 11765223     DOI: 10.1007/s00296-001-0141-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  19 in total

Review 1.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

2.  Meigs' syndrome: a rare cause of recurrent pleural effusion in scleroderma.

Authors:  Feng Su; Kristopher W Cummings; Hannah Krigman; Prabha Ranganathan
Journal:  Rheumatol Int       Date:  2012-04-27       Impact factor: 2.631

Review 3.  Gastroesophageal reflux disease and non-esophageal cancer.

Authors:  Fernando A M Herbella; Sebastião Pannocchia Neto; Ilka Lopes Santoro; Licia Caldas Figueiredo
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

4.  Possible anti-metastatic effect of iloprost in a patient with systemic sclerosis with lung cancer: a case study.

Authors:  Yavuz Pehlivan; Ibrahim Halil Turkbeyler; Ozan Balakan; Alper Sevinc; Mustafa Yilmaz; Kemal Bakir; Ahmet Mesut Onat
Journal:  Rheumatol Int       Date:  2011-03-30       Impact factor: 2.631

Review 5.  Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review.

Authors:  Eleni Tiniakou; Andrew L Mammen
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

6.  Small cell lung carcinoma associated with progressive systemic sclerosis.

Authors:  Kaushik Saha; Arnab Saha; Prabodh Panchadhyayee; Mrinmoy Mitra; Tara Sankar Malik; Pratik Barma; Santanu Ghosh
Journal:  Maedica (Buchar)       Date:  2013-09

Review 7.  Comorbidity burden in systemic sclerosis: beyond disease-specific complications.

Authors:  Eleni Pagkopoulou; Alexandra Arvanitaki; Dimitrios Daoussis; Alexandros Garyfallos; George Kitas; Theodoros Dimitroulas
Journal:  Rheumatol Int       Date:  2019-07-12       Impact factor: 2.631

8.  Risk of cancer in patients with scleroderma: a population based cohort study.

Authors:  C L Hill; A-M Nguyen; D Roder; P Roberts-Thomson
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

9.  Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study.

Authors:  Tim Y-T Lu; Catherine L Hill; Eliza K Pontifex; Peter J Roberts-Thomson
Journal:  Rheumatol Int       Date:  2008-02-16       Impact factor: 2.631

10.  Scleroderma lung disease.

Authors:  Jérôme Le Pavec; David Launay; Stephen C Mathai; Paul M Hassoun; Marc Humbert
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.